Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8666950 | 0.98 | DPP4 (0.41) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| SCHEMBL1569110 | 0.91 | DPP4 (0.38) | OPRM1DPP4AKR1C1 | |
| SCHEMBL12893261 | 0.89 | ESR2 (0.47) | AKR1C1SMN1; SMN2 | |
| SCHEMBL22348784 | 0.87 | HDAC6 (0.42) | SLC6A4SLC6A3OPRM1 | |
| SCHEMBL1256629 | 0.87 | ESR2 (0.46) | DPP4AKR1C1SMN1; SMN2 | |
| SCHEMBL1692027 | 0.85 | SLC6A3 (0.48) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL2360103 | 0.84 | OPRM1 (0.41) | OPRM1DPP4AKR1C1 | |
| Trimethylammonium SCHEMBL14720309 | 0.84 | OPRL1 (0.45) | SLC6A2SLC6A4SLC6A3SIGMAR1OPRM1 | |
| SCHEMBL1256618 | 0.78 | ELANE (0.46) | SLC6A2SLC6A3AKR1C1 | |
| SCHEMBL1692246 | 0.76 | SLC6A4 (0.41) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116113634-A | Modulus modifier and film thereof | 齐默尔根公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-108218824-B | Diphenyl [ b, d ] oxepane compound and preparation and application thereof | 中国科学院大连化学物理研究所 | 2020-06-26 | — | — | CN | disclosed |
| CN-108218824-A | Diphenyl simultaneously [b, d] oxepane hydride compounds and its preparation and application | 中国科学院大连化学物理研究所 | 2018-06-29 | — | — | CN | disclosed |
| US-6624175-B2 | 4-heterocyclic substituted quinoline derivative treats disorderes associated with pathogenic neurokinin-3 receptor, such as anxiety, depression, schizophrenia, obesity, chronic pulmonary obstructive disorder or pain | NEUROGEN CORPORATION | 2003-09-23 | — | — | US | disclosed |
| EP-1165542-B1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20020198232-A1 | 4-substituted quinoline derivatives | NEUROGEN CORPORATION (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2000058303-A9 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6413982-B1 | 5-ETHYL-5-PHENYL-2-(3-METHOXY-2-PHENYLQUINOLIN-4-YL)-IMIDAZO -LINE; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISEASES AND DISORDERS; BINDS WITH HIGH AFFINITY TO NEUROKININ-3 (NK-3) AND/OR GAMMA-AMINOBUTYRIC ACID RECEPTORS; SYNERGISTIC | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |
| EP-1165542-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6310212-B1 | BIND WITH HIGH AFFINITY TO GABA.SUB.A RECEPTORS; POTENTIATE THE EFFECTS OF OTHER CNS AGENTS. | NEUROGEN CORPORATION | 2001-10-30 | — | — | US | disclosed |
| WO-2000058313-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS GABA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000058303-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198232-A1 | 4-substituted quinoline derivatives | GABRA3, GABRB3, GABRR3 | SLC6A2 252/4885SLC6A4 306/4885SLC6A3 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.